메뉴 건너뛰기




Volumn 61, Issue 6, 2009, Pages 945-958

Angiogenesis in cutaneous disease: Part II

Author keywords

angiogenesis; antiangiogenic agents; dermatology

Indexed keywords

ALPHA2B INTERFERON; ANGIOGENIC FACTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BATIMASTAT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYCLOSPORIN A; DACARBAZINE; FOTEMUSTINE; FUMAGILLOL CHLOROACETYLCARBAMATE; IMIQUIMOD; MARIMASTAT; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; PACLITAXEL; PLACEBO; PREDNISONE; PROPRANOLOL; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RECOMBINANT ENDOSTATIN; SORAFENIB; TACROLIMUS; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

EID: 71549149661     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.05.053     Document Type: Review
Times cited : (12)

References (151)
  • 1
    • 85013312416 scopus 로고
    • Tumor angiogenesis: therapeutic implications
    • Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 2
    • 0030447757 scopus 로고    scopus 로고
    • Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels
    • Larcher F., Robles A.I., Duran H., Murillas R., Quintanilla M., Cano A., et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res 56 (1996) 5391-5396
    • (1996) Cancer Res , vol.56 , pp. 5391-5396
    • Larcher, F.1    Robles, A.I.2    Duran, H.3    Murillas, R.4    Quintanilla, M.5    Cano, A.6
  • 3
    • 0036054742 scopus 로고    scopus 로고
    • Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy
    • Conti C.J. Vascular endothelial growth factor: regulation in the mouse skin carcinogenesis model and use in antiangiogenesis cancer therapy. Oncologist 7 suppl 3 (2002) 4-11
    • (2002) Oncologist , vol.7 , Issue.SUPPL. 3 , pp. 4-11
    • Conti, C.J.1
  • 4
    • 0032770860 scopus 로고    scopus 로고
    • Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas
    • Streit M., Velasco P., Brown L.F., Skobe M., Richard L., Riccardi L., et al. Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 155 (1999) 441-452
    • (1999) Am J Pathol , vol.155 , pp. 441-452
    • Streit, M.1    Velasco, P.2    Brown, L.F.3    Skobe, M.4    Richard, L.5    Riccardi, L.6
  • 5
    • 0026006134 scopus 로고
    • Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma
    • Castle V., Varani J., Fligiel S., Prochownik E.V., and Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 87 (1991) 1883-1888
    • (1991) J Clin Invest , vol.87 , pp. 1883-1888
    • Castle, V.1    Varani, J.2    Fligiel, S.3    Prochownik, E.V.4    Dixit, V.5
  • 6
    • 0034980383 scopus 로고    scopus 로고
    • Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin
    • Shimizu T., Izumi H., Oga A., Furumoto H., Murakami T., Ofuji R., et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 202 (2001) 203-206
    • (2001) Dermatology , vol.202 , pp. 203-206
    • Shimizu, T.1    Izumi, H.2    Oga, A.3    Furumoto, H.4    Murakami, T.5    Ofuji, R.6
  • 7
    • 17444410011 scopus 로고    scopus 로고
    • Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin
    • Maubec E., Duvillard P., Velasco V., Crickx B., and Avril M.F. Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin. Anticancer Res 25 (2005) 1205-1210
    • (2005) Anticancer Res , vol.25 , pp. 1205-1210
    • Maubec, E.1    Duvillard, P.2    Velasco, V.3    Crickx, B.4    Avril, M.F.5
  • 8
    • 34250879547 scopus 로고    scopus 로고
    • Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab
    • Suen J.K., Bressler L., Shord S.S., Warso M., and Villano J.L. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs 18 (2007) 827-829
    • (2007) Anticancer Drugs , vol.18 , pp. 827-829
    • Suen, J.K.1    Bressler, L.2    Shord, S.S.3    Warso, M.4    Villano, J.L.5
  • 9
    • 34447517671 scopus 로고    scopus 로고
    • Treatment of recurrent squamous cell carcinoma of the skin with cetuximab
    • Bauman J.E., Eaton K.D., and Martins R.G. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol 143 (2007) 889-892
    • (2007) Arch Dermatol , vol.143 , pp. 889-892
    • Bauman, J.E.1    Eaton, K.D.2    Martins, R.G.3
  • 10
    • 46049104966 scopus 로고    scopus 로고
    • Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study
    • Thariat J., Ahamad A., El-Naggar A.K., Williams M.D., Holsinger F.C., Glisson B.S., et al. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 112 (2008) 2698-2709
    • (2008) Cancer , vol.112 , pp. 2698-2709
    • Thariat, J.1    Ahamad, A.2    El-Naggar, A.K.3    Williams, M.D.4    Holsinger, F.C.5    Glisson, B.S.6
  • 11
    • 33750380921 scopus 로고    scopus 로고
    • Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma
    • Ramadan K.M., McKenna K.E., and Morris T.C. Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma. Lancet Oncol 7 (2006) 958-959
    • (2006) Lancet Oncol , vol.7 , pp. 958-959
    • Ramadan, K.M.1    McKenna, K.E.2    Morris, T.C.3
  • 12
    • 28244462756 scopus 로고    scopus 로고
    • Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors
    • Koga K., Nabeshima K., Nishimura N., Shishime M., Nakayama J., and Iwasaki H. Microvessel density and HIF-1alpha expression correlate with malignant potential in fibrohistiocytic tumors. Eur J Dermatol 15 (2005) 465-469
    • (2005) Eur J Dermatol , vol.15 , pp. 465-469
    • Koga, K.1    Nabeshima, K.2    Nishimura, N.3    Shishime, M.4    Nakayama, J.5    Iwasaki, H.6
  • 13
    • 0034659658 scopus 로고    scopus 로고
    • Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo
    • Westphal J.R., Van't Hullenaar R., Peek R., Willems R.W., Crickard K., Crickard U., et al. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 86 (2000) 768-776
    • (2000) Int J Cancer , vol.86 , pp. 768-776
    • Westphal, J.R.1    Van't Hullenaar, R.2    Peek, R.3    Willems, R.W.4    Crickard, K.5    Crickard, U.6
  • 14
    • 0034283023 scopus 로고    scopus 로고
    • Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts
    • Rofstad E.K., and Halsor E.F. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res 60 (2000) 4932-4938
    • (2000) Cancer Res , vol.60 , pp. 4932-4938
    • Rofstad, E.K.1    Halsor, E.F.2
  • 15
    • 0042674080 scopus 로고    scopus 로고
    • Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients
    • Schadendorf D., Dorn-Beineke A., Borelli S., Riethmuller G., and Pantel K. Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients. Exp Dermatol 12 (2003) 165-171
    • (2003) Exp Dermatol , vol.12 , pp. 165-171
    • Schadendorf, D.1    Dorn-Beineke, A.2    Borelli, S.3    Riethmuller, G.4    Pantel, K.5
  • 16
    • 0032960519 scopus 로고    scopus 로고
    • Role of interleukin-8 in tumor growth and metastasis of human melanoma
    • Bar-Eli M. Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67 (1999) 12-18
    • (1999) Pathobiology , vol.67 , pp. 12-18
    • Bar-Eli, M.1
  • 17
    • 9744253054 scopus 로고    scopus 로고
    • Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3 K signaling
    • Graells J., Vinyals A., Figueras A., Llorens A., Moreno A., Marcoval J., et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3 K signaling. J Invest Dermatol 123 (2004) 1151-1161
    • (2004) J Invest Dermatol , vol.123 , pp. 1151-1161
    • Graells, J.1    Vinyals, A.2    Figueras, A.3    Llorens, A.4    Moreno, A.5    Marcoval, J.6
  • 18
    • 1942442169 scopus 로고    scopus 로고
    • Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice
    • Bedogni B., O'Neill M.S., Welford S.M., Bouley D.M., Giaccia A.J., Denko N.C., et al. Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res 64 (2004) 2552-2560
    • (2004) Cancer Res , vol.64 , pp. 2552-2560
    • Bedogni, B.1    O'Neill, M.S.2    Welford, S.M.3    Bouley, D.M.4    Giaccia, A.J.5    Denko, N.C.6
  • 21
    • 33749472634 scopus 로고    scopus 로고
    • Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival
    • Karst A.M., Dai D.L., Cheng J.Q., and Li G. Role of p53 up-regulated modulator of apoptosis and phosphorylated Akt in melanoma cell growth, apoptosis, and patient survival. Cancer Res 66 (2006) 9221-9226
    • (2006) Cancer Res , vol.66 , pp. 9221-9226
    • Karst, A.M.1    Dai, D.L.2    Cheng, J.Q.3    Li, G.4
  • 23
    • 33947355893 scopus 로고    scopus 로고
    • Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression
    • Kurschat P., Eming S., Nashan D., Krieg T., and Mauch C. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. Br J Dermatol 156 (2007) 653-658
    • (2007) Br J Dermatol , vol.156 , pp. 653-658
    • Kurschat, P.1    Eming, S.2    Nashan, D.3    Krieg, T.4    Mauch, C.5
  • 25
    • 1642535552 scopus 로고    scopus 로고
    • Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis
    • Mendoza L., Valcarcel M., Carrascal T., Egilegor E., Salado C., Sim B.K., et al. Inhibition of cytokine-induced microvascular arrest of tumor cells by recombinant endostatin prevents experimental hepatic melanoma metastasis. Cancer Res 64 (2004) 304-310
    • (2004) Cancer Res , vol.64 , pp. 304-310
    • Mendoza, L.1    Valcarcel, M.2    Carrascal, T.3    Egilegor, E.4    Salado, C.5    Sim, B.K.6
  • 26
    • 0031454617 scopus 로고    scopus 로고
    • Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
    • O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88 (1997) 277-285
    • (1997) Cell , vol.88 , pp. 277-285
    • O'Reilly, M.S.1    Boehm, T.2    Shing, Y.3    Fukai, N.4    Vasios, G.5    Lane, W.S.6
  • 27
    • 0002158323 scopus 로고    scopus 로고
    • Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile
    • Sim B.K., Fogler W.E., Zhou X.H., Liang H., Madsen J.W., Luu K., et al. Zinc ligand-disrupted recombinant human endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3 (1999) 41-51
    • (1999) Angiogenesis , vol.3 , pp. 41-51
    • Sim, B.K.1    Fogler, W.E.2    Zhou, X.H.3    Liang, H.4    Madsen, J.W.5    Luu, K.6
  • 28
    • 42149105036 scopus 로고    scopus 로고
    • Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model
    • Wu D.S., Wu C.M., Huang T.H., and Xie Q.D. Combined effects of radiotherapy and endostatin gene therapy in melanoma tumor model. Radiat Environ Biophys 47 (2008) 285-291
    • (2008) Radiat Environ Biophys , vol.47 , pp. 285-291
    • Wu, D.S.1    Wu, C.M.2    Huang, T.H.3    Xie, Q.D.4
  • 29
    • 34249011849 scopus 로고    scopus 로고
    • Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents
    • Moschos S.J., Odoux C., Land S.R., Agarwala S., Friedland D., Volker K.M., et al. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res 17 (2007) 193-200
    • (2007) Melanoma Res , vol.17 , pp. 193-200
    • Moschos, S.J.1    Odoux, C.2    Land, S.R.3    Agarwala, S.4    Friedland, D.5    Volker, K.M.6
  • 30
    • 46249106819 scopus 로고    scopus 로고
    • Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma
    • Gonzalez-Cao M., Viteri S., Diaz-Lagares A., Gonzalez A., Redondo P., Nieto Y., et al. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 74 (2008) 12-16
    • (2008) Oncology , vol.74 , pp. 12-16
    • Gonzalez-Cao, M.1    Viteri, S.2    Diaz-Lagares, A.3    Gonzalez, A.4    Redondo, P.5    Nieto, Y.6
  • 31
    • 34547451603 scopus 로고    scopus 로고
    • A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
    • Varker K.A., Biber J.E., Kefauver C., Jensen R., Lehman A., Young D., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14 (2007) 2367-2376
    • (2007) Ann Surg Oncol , vol.14 , pp. 2367-2376
    • Varker, K.A.1    Biber, J.E.2    Kefauver, C.3    Jensen, R.4    Lehman, A.5    Young, D.6
  • 32
    • 36849048282 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma
    • Terheyden P., Hofmann M.A., Weininger M., Brocker E.B., and Becker J.C. Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 133 (2007) 897-901
    • (2007) J Cancer Res Clin Oncol , vol.133 , pp. 897-901
    • Terheyden, P.1    Hofmann, M.A.2    Weininger, M.3    Brocker, E.B.4    Becker, J.C.5
  • 33
    • 33748325763 scopus 로고    scopus 로고
    • Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis
    • Eisen T., Ahmad T., Flaherty K.T., Gore M., Kaye S., Marais R., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586
    • (2006) Br J Cancer , vol.95 , pp. 581-586
    • Eisen, T.1    Ahmad, T.2    Flaherty, K.T.3    Gore, M.4    Kaye, S.5    Marais, R.6
  • 34
    • 51049095131 scopus 로고    scopus 로고
    • A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel
    • Flaherty K.T., Schiller J., Schuchter L.M., Liu G., Tuveson D.A., Redlinger M., et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14 (2008) 4836-4842
    • (2008) Clin Cancer Res , vol.14 , pp. 4836-4842
    • Flaherty, K.T.1    Schiller, J.2    Schuchter, L.M.3    Liu, G.4    Tuveson, D.A.5    Redlinger, M.6
  • 35
    • 43749110700 scopus 로고    scopus 로고
    • Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group
    • McDermott D.F., Sosman J.A., Gonzalez R., Hodi F.S., Linette G.P., Richards J., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26 (2008) 2178-2185
    • (2008) J Clin Oncol , vol.26 , pp. 2178-2185
    • McDermott, D.F.1    Sosman, J.A.2    Gonzalez, R.3    Hodi, F.S.4    Linette, G.P.5    Richards, J.6
  • 36
    • 49249137986 scopus 로고    scopus 로고
    • Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2
    • Molhoek K.R., Griesemann H., Shu J., Gershenwald J.E., Brautigan D.L., and Slingluff Jr. C.L. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 68 (2008) 4392-4397
    • (2008) Cancer Res , vol.68 , pp. 4392-4397
    • Molhoek, K.R.1    Griesemann, H.2    Shu, J.3    Gershenwald, J.E.4    Brautigan, D.L.5    Slingluff Jr., C.L.6
  • 37
    • 38749126155 scopus 로고    scopus 로고
    • Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines
    • Bundscherer A., Hafner C., Maisch T., Becker B., Landthaler M., and Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 19 (2008) 547-553
    • (2008) Oncol Rep , vol.19 , pp. 547-553
    • Bundscherer, A.1    Hafner, C.2    Maisch, T.3    Becker, B.4    Landthaler, M.5    Vogt, T.6
  • 38
    • 47349099502 scopus 로고    scopus 로고
    • Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
    • Lasithiotakis K.G., Sinnberg T.W., Schittek B., Flaherty K.T., Kulms D., Maczey E., et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol 128 (2008) 2013-2023
    • (2008) J Invest Dermatol , vol.128 , pp. 2013-2023
    • Lasithiotakis, K.G.1    Sinnberg, T.W.2    Schittek, B.3    Flaherty, K.T.4    Kulms, D.5    Maczey, E.6
  • 39
    • 34249799034 scopus 로고    scopus 로고
    • CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model
    • Thallinger C., Poeppl W., Pratscher B., Mayerhofer M., Valent P., Tappeiner G., et al. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology 79 (2007) 207-213
    • (2007) Pharmacology , vol.79 , pp. 207-213
    • Thallinger, C.1    Poeppl, W.2    Pratscher, B.3    Mayerhofer, M.4    Valent, P.5    Tappeiner, G.6
  • 40
    • 0028129059 scopus 로고
    • Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor
    • Chirivi R.G., Garofalo A., Crimmin M.J., Bawden L.J., Stoppacciaro A., Brown P.D., et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58 (1994) 460-464
    • (1994) Int J Cancer , vol.58 , pp. 460-464
    • Chirivi, R.G.1    Garofalo, A.2    Crimmin, M.J.3    Bawden, L.J.4    Stoppacciaro, A.5    Brown, P.D.6
  • 41
    • 0036830078 scopus 로고    scopus 로고
    • Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group
    • Quirt I., Bodurth A., Lohmann R., Rusthoven J., Belanger K., Young V., et al. Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 20 (2002) 431-437
    • (2002) Invest New Drugs , vol.20 , pp. 431-437
    • Quirt, I.1    Bodurth, A.2    Lohmann, R.3    Rusthoven, J.4    Belanger, K.5    Young, V.6
  • 42
    • 39049092700 scopus 로고    scopus 로고
    • Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines
    • Sorolla A., Yeramian A., Dolcet X., Perez de Santos A.M., Llobet D., Schoenenberger J.A., et al. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol 158 (2008) 496-504
    • (2008) Br J Dermatol , vol.158 , pp. 496-504
    • Sorolla, A.1    Yeramian, A.2    Dolcet, X.3    Perez de Santos, A.M.4    Llobet, D.5    Schoenenberger, J.A.6
  • 43
    • 20444364475 scopus 로고    scopus 로고
    • A phase II study of bortezomib in the treatment of metastatic malignant melanoma
    • Markovic S.N., Geyer S.M., Dawkins F., Sharfman W., Albertini M., Maples W., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589
    • (2005) Cancer , vol.103 , pp. 2584-2589
    • Markovic, S.N.1    Geyer, S.M.2    Dawkins, F.3    Sharfman, W.4    Albertini, M.5    Maples, W.6
  • 44
    • 34249990658 scopus 로고    scopus 로고
    • A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    • Markovic S.N., Suman V.J., Rao R.A., Ingle J.N., Kaur J.S., Erickson L.A., et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30 (2007) 303-309
    • (2007) Am J Clin Oncol , vol.30 , pp. 303-309
    • Markovic, S.N.1    Suman, V.J.2    Rao, R.A.3    Ingle, J.N.4    Kaur, J.S.5    Erickson, L.A.6
  • 45
    • 38849123472 scopus 로고    scopus 로고
    • Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma
    • Chumsri S., Zhao M., Garofalo M., Burger A., Hamburger A., Zhao F., et al. Inhibition of the mammalian target of rapamycin (mTOR) in a case of refractory primary cutaneous anaplastic large cell lymphoma. Leuk Lymphoma 49 (2008) 359-361
    • (2008) Leuk Lymphoma , vol.49 , pp. 359-361
    • Chumsri, S.1    Zhao, M.2    Garofalo, M.3    Burger, A.4    Hamburger, A.5    Zhao, F.6
  • 46
    • 0029834676 scopus 로고    scopus 로고
    • Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome
    • Zhang Q., Nowak I., Vonderheid E.C., Rook A.H., Kadin M.E., Nowell P.C., et al. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sézary syndrome. Proc Natl Acad Sci U S A 93 (1996) 9148-9153
    • (1996) Proc Natl Acad Sci U S A , vol.93 , pp. 9148-9153
    • Zhang, Q.1    Nowak, I.2    Vonderheid, E.C.3    Rook, A.H.4    Kadin, M.E.5    Nowell, P.C.6
  • 47
    • 34948833649 scopus 로고    scopus 로고
    • Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
    • Zinzani P.L., Musuraca G., Tani M., Stefoni V., Marchi E., Fina M., et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (2007) 4293-4297
    • (2007) J Clin Oncol , vol.25 , pp. 4293-4297
    • Zinzani, P.L.1    Musuraca, G.2    Tani, M.3    Stefoni, V.4    Marchi, E.5    Fina, M.6
  • 48
    • 0035866812 scopus 로고    scopus 로고
    • The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B
    • Montaner S., Sodhi A., Pece S., Mesri E.A., and Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 61 (2001) 2641-2648
    • (2001) Cancer Res , vol.61 , pp. 2641-2648
    • Montaner, S.1    Sodhi, A.2    Pece, S.3    Mesri, E.A.4    Gutkind, J.S.5
  • 49
    • 0034282553 scopus 로고    scopus 로고
    • The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha
    • Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res 60 (2000) 4873-4880
    • (2000) Cancer Res , vol.60 , pp. 4873-4880
    • Sodhi, A.1    Montaner, S.2    Patel, V.3    Zohar, M.4    Bais, C.5    Mesri, E.A.6
  • 50
    • 0037772150 scopus 로고    scopus 로고
    • Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes
    • Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3 (2003) 23-36
    • (2003) Cancer Cell , vol.3 , pp. 23-36
    • Montaner, S.1    Sodhi, A.2    Molinolo, A.3    Bugge, T.H.4    Sawai, E.T.5    He, Y.6
  • 51
    • 0029993747 scopus 로고    scopus 로고
    • Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma
    • Brown L.F., Tognazzi K., Dvorak H.F., and Harrist T.J. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 148 (1996) 1065-1074
    • (1996) Am J Pathol , vol.148 , pp. 1065-1074
    • Brown, L.F.1    Tognazzi, K.2    Dvorak, H.F.3    Harrist, T.J.4
  • 52
    • 0029847089 scopus 로고    scopus 로고
    • Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma
    • Cornali E., Zietz C., Benelli R., Weninger W., Masiello L., Breier G., et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 149 (1996) 1851-1869
    • (1996) Am J Pathol , vol.149 , pp. 1851-1869
    • Cornali, E.1    Zietz, C.2    Benelli, R.3    Weninger, W.4    Masiello, L.5    Breier, G.6
  • 53
    • 33644783914 scopus 로고    scopus 로고
    • Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
    • Ferrario A., and Gomer C.J. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. J Environ Pathol Toxicol Oncol 25 (2006) 251-259
    • (2006) J Environ Pathol Toxicol Oncol , vol.25 , pp. 251-259
    • Ferrario, A.1    Gomer, C.J.2
  • 55
    • 33645458234 scopus 로고    scopus 로고
    • Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation
    • Campistol J.M., Eris J., Oberbauer R., Friend P., Hutchison B., Morales J.M., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581-589
    • (2006) J Am Soc Nephrol , vol.17 , pp. 581-589
    • Campistol, J.M.1    Eris, J.2    Oberbauer, R.3    Friend, P.4    Hutchison, B.5    Morales, J.M.6
  • 57
    • 44249117090 scopus 로고    scopus 로고
    • Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris
    • Saggar S., Zeichner J.A., Brown T.T., Phelps R.G., and Cohen S.R. Kaposi's sarcoma resolves after sirolimus therapy in a patient with pemphigus vulgaris. Arch Dermatol 144 (2008) 654-657
    • (2008) Arch Dermatol , vol.144 , pp. 654-657
    • Saggar, S.1    Zeichner, J.A.2    Brown, T.T.3    Phelps, R.G.4    Cohen, S.R.5
  • 58
    • 44249102076 scopus 로고    scopus 로고
    • Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment
    • Guenova E., Metzler G., Hoetzenecker W., Berneburg M., and Rocken M. Classic Mediterranean Kaposi's sarcoma regression with sirolimus treatment. Arch Dermatol 144 (2008) 692-693
    • (2008) Arch Dermatol , vol.144 , pp. 692-693
    • Guenova, E.1    Metzler, G.2    Hoetzenecker, W.3    Berneburg, M.4    Rocken, M.5
  • 59
    • 0034872059 scopus 로고    scopus 로고
    • Management of Kaposi sarcoma: the role of interferon and thalidomide
    • Krown S.E. Management of Kaposi sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 13 (2001) 374-381
    • (2001) Curr Opin Oncol , vol.13 , pp. 374-381
    • Krown, S.E.1
  • 60
    • 40649102193 scopus 로고    scopus 로고
    • Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients
    • Celestin Schartz N.E., Chevret S., Paz C., Kerob D., Verola O., Morel P., et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: a phase I to II, open-label trial in 17 patients. J Am Acad Dermatol 58 (2008) 585-591
    • (2008) J Am Acad Dermatol , vol.58 , pp. 585-591
    • Celestin Schartz, N.E.1    Chevret, S.2    Paz, C.3    Kerob, D.4    Verola, O.5    Morel, P.6
  • 62
    • 39149092712 scopus 로고    scopus 로고
    • Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies
    • Koontz B.F., Miles E.F., Rubio M.A., Madden J.F., Fisher S.R., Scher R.L., et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 30 (2008) 262-266
    • (2008) Head Neck , vol.30 , pp. 262-266
    • Koontz, B.F.1    Miles, E.F.2    Rubio, M.A.3    Madden, J.F.4    Fisher, S.R.5    Scher, R.L.6
  • 65
    • 0033089048 scopus 로고    scopus 로고
    • Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta
    • Bielenberg D.R., Bucana C.D., Sanchez R., Mulliken J.B., Folkman J., and Fidler I.J. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 14 (1999) 401-408
    • (1999) Int J Oncol , vol.14 , pp. 401-408
    • Bielenberg, D.R.1    Bucana, C.D.2    Sanchez, R.3    Mulliken, J.B.4    Folkman, J.5    Fidler, I.J.6
  • 66
    • 0035180453 scopus 로고    scopus 로고
    • Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells
    • Yu Y., Varughese J., Brown L.F., Mulliken J.B., and Bischoff J. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Am J Pathol 159 (2001) 2271-2280
    • (2001) Am J Pathol , vol.159 , pp. 2271-2280
    • Yu, Y.1    Varughese, J.2    Brown, L.F.3    Mulliken, J.B.4    Bischoff, J.5
  • 68
    • 0037188545 scopus 로고    scopus 로고
    • Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis
    • Ritter M.R., Dorrell M.I., Edmonds J., Friedlander S.F., and Friedlander M. Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A 99 (2002) 7455-7460
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 7455-7460
    • Ritter, M.R.1    Dorrell, M.I.2    Edmonds, J.3    Friedlander, S.F.4    Friedlander, M.5
  • 69
    • 0028939303 scopus 로고
    • Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases
    • Taraboletti G., Garofalo A., Belotti D., Drudis T., Borsotti P., Scanziani E., et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87 (1995) 293-298
    • (1995) J Natl Cancer Inst , vol.87 , pp. 293-298
    • Taraboletti, G.1    Garofalo, A.2    Belotti, D.3    Drudis, T.4    Borsotti, P.5    Scanziani, E.6
  • 70
    • 0035863487 scopus 로고    scopus 로고
    • Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas
    • Vergani V., Garofalo A., Bani M.R., Borsotti P., Parker M.P., Drudis T., et al. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer 91 (2001) 241-247
    • (2001) Int J Cancer , vol.91 , pp. 241-247
    • Vergani, V.1    Garofalo, A.2    Bani, M.R.3    Borsotti, P.4    Parker, M.P.5    Drudis, T.6
  • 71
    • 0029915612 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
    • Ramakrishnan S., Olson T.A., Bautch V.L., and Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56 (1996) 1324-1330
    • (1996) Cancer Res , vol.56 , pp. 1324-1330
    • Ramakrishnan, S.1    Olson, T.A.2    Bautch, V.L.3    Mohanraj, D.4
  • 72
    • 0033563118 scopus 로고    scopus 로고
    • A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470
    • Liekens S., Verbeken E., Vandeputte M., De Clercq E., and Neyts J. A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res 59 (1999) 2376-2383
    • (1999) Cancer Res , vol.59 , pp. 2376-2383
    • Liekens, S.1    Verbeken, E.2    Vandeputte, M.3    De Clercq, E.4    Neyts, J.5
  • 74
    • 4644310913 scopus 로고    scopus 로고
    • Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream
    • Welsh O., Olazaran Z., Gomez M., Salas J., and Berman B. Treatment of infantile hemangiomas with short-term application of imiquimod 5% cream. J Am Acad Dermatol 51 (2004) 639-642
    • (2004) J Am Acad Dermatol , vol.51 , pp. 639-642
    • Welsh, O.1    Olazaran, Z.2    Gomez, M.3    Salas, J.4    Berman, B.5
  • 76
    • 33845878022 scopus 로고    scopus 로고
    • Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study
    • Ho N.T., Lansang P., and Pope E. Topical imiquimod in the treatment of infantile hemangiomas: a retrospective study. J Am Acad Dermatol 56 (2007) 63-68
    • (2007) J Am Acad Dermatol , vol.56 , pp. 63-68
    • Ho, N.T.1    Lansang, P.2    Pope, E.3
  • 77
    • 65649129285 scopus 로고    scopus 로고
    • A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma
    • McCuaig C.C., Dubois J., Powell J., Belleville C., David M., Rousseau E., et al. A phase II, open-label study of the efficacy and safety of imiquimod in the treatment of superficial and mixed infantile hemangioma. Pediatr Dermatol 26 (2009) 203-212
    • (2009) Pediatr Dermatol , vol.26 , pp. 203-212
    • McCuaig, C.C.1    Dubois, J.2    Powell, J.3    Belleville, C.4    David, M.5    Rousseau, E.6
  • 78
    • 58149330199 scopus 로고    scopus 로고
    • Efficacy of topical application of eosin for ulcerated hemangiomas
    • Arbiser J.L. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol 60 (2009) 350-351
    • (2009) J Am Acad Dermatol , vol.60 , pp. 350-351
    • Arbiser, J.L.1
  • 80
    • 0030948107 scopus 로고    scopus 로고
    • Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases
    • Mentzel T., Beham A., Calonje E., Katenkamp D., and Fletcher C.D. Epithelioid hemangioendothelioma of skin and soft tissues: clinicopathologic and immunohistochemical study of 30 cases. Am J Surg Pathol 21 (1997) 363-374
    • (1997) Am J Surg Pathol , vol.21 , pp. 363-374
    • Mentzel, T.1    Beham, A.2    Calonje, E.3    Katenkamp, D.4    Fletcher, C.D.5
  • 81
    • 0030692665 scopus 로고    scopus 로고
    • Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo
    • Lannutti B.J., Gately S.T., Quevedo M.E., Soff G.A., and Paller A.S. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 57 (1997) 5277-5280
    • (1997) Cancer Res , vol.57 , pp. 5277-5280
    • Lannutti, B.J.1    Gately, S.T.2    Quevedo, M.E.3    Soff, G.A.4    Paller, A.S.5
  • 83
    • 43049117177 scopus 로고    scopus 로고
    • Pulmonary epithelioid haemangioendothelioma and bevacizumab
    • Belmont L., Zemoura L., and Couderc L.J. Pulmonary epithelioid haemangioendothelioma and bevacizumab. J Thorac Oncol 3 (2008) 557-558
    • (2008) J Thorac Oncol , vol.3 , pp. 557-558
    • Belmont, L.1    Zemoura, L.2    Couderc, L.J.3
  • 85
    • 34247373748 scopus 로고    scopus 로고
    • AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo
    • Perry B., Banyard J., McLaughlin E.R., Watnick R., Sohn A., Brindley D.N., et al. AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol 143 (2007) 504-506
    • (2007) Arch Dermatol , vol.143 , pp. 504-506
    • Perry, B.1    Banyard, J.2    McLaughlin, E.R.3    Watnick, R.4    Sohn, A.5    Brindley, D.N.6
  • 86
    • 33644605419 scopus 로고    scopus 로고
    • Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies
    • Marler J.J., Fishman S.J., Kilroy S.M., Fang J., Upton J., Mulliken J.B., et al. Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116 (2005) 38-45
    • (2005) Pediatrics , vol.116 , pp. 38-45
    • Marler, J.J.1    Fishman, S.J.2    Kilroy, S.M.3    Fang, J.4    Upton, J.5    Mulliken, J.B.6
  • 87
    • 0030460775 scopus 로고    scopus 로고
    • Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2
    • Vikkula M., Boon L.M., Carraway III K.L., Calvert J.T., Diamonti A.J., Goumnerov B., et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87 (1996) 1181-1190
    • (1996) Cell , vol.87 , pp. 1181-1190
    • Vikkula, M.1    Boon, L.M.2    Carraway III, K.L.3    Calvert, J.T.4    Diamonti, A.J.5    Goumnerov, B.6
  • 88
    • 38149000984 scopus 로고    scopus 로고
    • Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo
    • Shirazi F., Cohen C., Fried L., and Arbiser J.L. Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol 5 (2007) 233-236
    • (2007) Lymphat Res Biol , vol.5 , pp. 233-236
    • Shirazi, F.1    Cohen, C.2    Fried, L.3    Arbiser, J.L.4
  • 89
    • 38949157092 scopus 로고    scopus 로고
    • Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks
    • Phung T.L., Oble D.A., Jia W., Benjamin L.E., Mihm Jr. M.C., and Nelson J.S. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med 40 (2008) 1-5
    • (2008) Lasers Surg Med , vol.40 , pp. 1-5
    • Phung, T.L.1    Oble, D.A.2    Jia, W.3    Benjamin, L.E.4    Mihm Jr., M.C.5    Nelson, J.S.6
  • 90
    • 34848879004 scopus 로고    scopus 로고
    • Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair
    • Mace K.A., Yu D.H., Paydar K.Z., Boudreau N., and Young D.M. Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen 15 (2007) 636-645
    • (2007) Wound Repair Regen , vol.15 , pp. 636-645
    • Mace, K.A.1    Yu, D.H.2    Paydar, K.Z.3    Boudreau, N.4    Young, D.M.5
  • 93
    • 55449131051 scopus 로고    scopus 로고
    • Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks
    • Chang C.J., Hsiao Y.C., Mihm Jr. M.C., and Nelson J.S. Pilot study examining the combined use of pulsed dye laser and topical imiquimod versus laser alone for treatment of port wine stain birthmarks. Lasers Surg Med 40 (2008) 605-610
    • (2008) Lasers Surg Med , vol.40 , pp. 605-610
    • Chang, C.J.1    Hsiao, Y.C.2    Mihm Jr., M.C.3    Nelson, J.S.4
  • 94
    • 0016730483 scopus 로고
    • Tumor angiogenic factor and human skin tumors
    • Wolf Jr. J.E., and Hubler Jr. W.R. Tumor angiogenic factor and human skin tumors. Arch Dermatol 111 (1975) 321-327
    • (1975) Arch Dermatol , vol.111 , pp. 321-327
    • Wolf Jr., J.E.1    Hubler Jr., W.R.2
  • 96
    • 0034198659 scopus 로고    scopus 로고
    • Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis
    • Yuan K., Jin Y.T., and Lin M.T. Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis. J Periodontal Res 35 (2000) 165-171
    • (2000) J Periodontal Res , vol.35 , pp. 165-171
    • Yuan, K.1    Jin, Y.T.2    Lin, M.T.3
  • 97
    • 0034180790 scopus 로고    scopus 로고
    • The detection and comparison of angiogenesis-associated factors in pyogenic granuloma by immunohistochemistry
    • Yuan K., Jin Y.T., and Lin M.T. The detection and comparison of angiogenesis-associated factors in pyogenic granuloma by immunohistochemistry. J Periodontol 71 (2000) 701-709
    • (2000) J Periodontol , vol.71 , pp. 701-709
    • Yuan, K.1    Jin, Y.T.2    Lin, M.T.3
  • 98
    • 0026492897 scopus 로고
    • Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma
    • Saarialho-Kere U.K., Chang E.S., Welgus H.G., and Parks W.C. Distinct localization of collagenase and tissue inhibitor of metalloproteinases expression in wound healing associated with ulcerative pyogenic granuloma. J Clin Invest 90 (1992) 1952-1957
    • (1992) J Clin Invest , vol.90 , pp. 1952-1957
    • Saarialho-Kere, U.K.1    Chang, E.S.2    Welgus, H.G.3    Parks, W.C.4
  • 102
    • 35448933306 scopus 로고    scopus 로고
    • Pyogenic granuloma in children: treatment with topical imiquimod
    • Fallah H., Fischer G., and Zagarella S. Pyogenic granuloma in children: treatment with topical imiquimod. Australas J Dermatol 48 (2007) 217-220
    • (2007) Australas J Dermatol , vol.48 , pp. 217-220
    • Fallah, H.1    Fischer, G.2    Zagarella, S.3
  • 103
    • 45149087717 scopus 로고    scopus 로고
    • Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream
    • Georgiou S., Monastirli A., Pasmatzi E., and Tsambaos D. Pyogenic granuloma: complete remission under occlusive imiquimod 5% cream. Clin Exp Dermatol 33 (2008) 454-456
    • (2008) Clin Exp Dermatol , vol.33 , pp. 454-456
    • Georgiou, S.1    Monastirli, A.2    Pasmatzi, E.3    Tsambaos, D.4
  • 104
    • 33646561215 scopus 로고    scopus 로고
    • Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream
    • Goldenberg G., Krowchuk D.P., and Jorizzo J.L. Successful treatment of a therapy-resistant pyogenic granuloma with topical imiquimod 5% cream. J Dermatolog Treat 17 (2006) 121-123
    • (2006) J Dermatolog Treat , vol.17 , pp. 121-123
    • Goldenberg, G.1    Krowchuk, D.P.2    Jorizzo, J.L.3
  • 105
    • 0036713778 scopus 로고    scopus 로고
    • TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
    • Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4 (2002) 648-657
    • (2002) Nat Cell Biol , vol.4 , pp. 648-657
    • Inoki, K.1    Li, Y.2    Zhu, T.3    Wu, J.4    Guan, K.L.5
  • 106
    • 0036714127 scopus 로고    scopus 로고
    • Akt regulates growth by directly phosphorylating Tsc2
    • Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4 (2002) 658-665
    • (2002) Nat Cell Biol , vol.4 , pp. 658-665
    • Potter, C.J.1    Pedraza, L.G.2    Xu, T.3
  • 108
    • 34447272449 scopus 로고    scopus 로고
    • Tuberous sclerosis complex: advances in diagnosis, genetics, and management
    • Schwartz R.A., Fernandez G., Kotulska K., and Jozwiak S. Tuberous sclerosis complex: advances in diagnosis, genetics, and management. J Am Acad Dermatol 57 (2007) 189-202
    • (2007) J Am Acad Dermatol , vol.57 , pp. 189-202
    • Schwartz, R.A.1    Fernandez, G.2    Kotulska, K.3    Jozwiak, S.4
  • 110
    • 0141705466 scopus 로고    scopus 로고
    • Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin
    • El-Hashemite N., Walker V., Zhang H., and Kwiatkowski D.J. Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res 63 (2003) 5173-5177
    • (2003) Cancer Res , vol.63 , pp. 5173-5177
    • El-Hashemite, N.1    Walker, V.2    Zhang, H.3    Kwiatkowski, D.J.4
  • 111
    • 0037108682 scopus 로고    scopus 로고
    • Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors
    • Kenerson H.L., Aicher L.D., True L.D., and Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62 (2002) 5645-5650
    • (2002) Cancer Res , vol.62 , pp. 5645-5650
    • Kenerson, H.L.1    Aicher, L.D.2    True, L.D.3    Yeung, R.S.4
  • 112
    • 41449112167 scopus 로고    scopus 로고
    • Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
    • Rauktys A., Lee N., Lee L., and Dabora S.L. Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model. BMC Dermatol 8 (2008) 1
    • (2008) BMC Dermatol , vol.8 , pp. 1
    • Rauktys, A.1    Lee, N.2    Lee, L.3    Dabora, S.L.4
  • 113
    • 47549093135 scopus 로고    scopus 로고
    • The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis
    • Hofbauer G.F., Marcollo-Pini A., Corsenca A., Kistler A.D., French L.E., Wuthrich R.P., et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 159 (2008) 473-475
    • (2008) Br J Dermatol , vol.159 , pp. 473-475
    • Hofbauer, G.F.1    Marcollo-Pini, A.2    Corsenca, A.3    Kistler, A.D.4    French, L.E.5    Wuthrich, R.P.6
  • 114
    • 0027980960 scopus 로고
    • Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis
    • Detmar M., Brown L.F., Claffey K.P., Yeo K.T., Kocher O., Jackman R.W., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
    • (1994) J Exp Med , vol.180 , pp. 1141-1146
    • Detmar, M.1    Brown, L.F.2    Claffey, K.P.3    Yeo, K.T.4    Kocher, O.5    Jackman, R.W.6
  • 115
    • 0033387917 scopus 로고    scopus 로고
    • Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis
    • Bhushan M., McLaughlin B., Weiss J.B., and Griffiths C.E. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 141 (1999) 1054-1060
    • (1999) Br J Dermatol , vol.141 , pp. 1054-1060
    • Bhushan, M.1    McLaughlin, B.2    Weiss, J.B.3    Griffiths, C.E.4
  • 116
    • 0038644624 scopus 로고    scopus 로고
    • Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis
    • Xia Y.P., Li B., Hylton D., Detmar M., Yancopoulos G.D., and Rudge J.S. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102 (2003) 161-168
    • (2003) Blood , vol.102 , pp. 161-168
    • Xia, Y.P.1    Li, B.2    Hylton, D.3    Detmar, M.4    Yancopoulos, G.D.5    Rudge, J.S.6
  • 117
    • 42349097330 scopus 로고    scopus 로고
    • Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF
    • Man X.Y., Yang X.H., Cai S.Q., Bu Z.Y., and Zheng M. Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF. J Cell Mol Med 12 (2008) 649-660
    • (2008) J Cell Mol Med , vol.12 , pp. 649-660
    • Man, X.Y.1    Yang, X.H.2    Cai, S.Q.3    Bu, Z.Y.4    Zheng, M.5
  • 118
    • 20444497652 scopus 로고    scopus 로고
    • Psoriasis-recent advances in understanding its pathogenesis and treatment
    • Krueger G., and Ellis C.N. Psoriasis-recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 53 (2005) S94-100
    • (2005) J Am Acad Dermatol , vol.53
    • Krueger, G.1    Ellis, C.N.2
  • 119
    • 0028223727 scopus 로고
    • Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis
    • Nickoloff B.J., Mitra R.S., Varani J., Dixit V.M., and Polverini P.J. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 144 (1994) 820-828
    • (1994) Am J Pathol , vol.144 , pp. 820-828
    • Nickoloff, B.J.1    Mitra, R.S.2    Varani, J.3    Dixit, V.M.4    Polverini, P.J.5
  • 120
    • 0035012596 scopus 로고    scopus 로고
    • Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis
    • Kuroda K., Sapadin A., Shoji T., Fleischmajer R., and Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116 (2001) 713-720
    • (2001) J Invest Dermatol , vol.116 , pp. 713-720
    • Kuroda, K.1    Sapadin, A.2    Shoji, T.3    Fleischmajer, R.4    Lebwohl, M.5
  • 121
    • 0030480322 scopus 로고    scopus 로고
    • Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    • Suri C., Jones P.F., Patan S., Bartunkova S., Maisonpierre P.C., Davis S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87 (1996) 1171-1180
    • (1996) Cell , vol.87 , pp. 1171-1180
    • Suri, C.1    Jones, P.F.2    Patan, S.3    Bartunkova, S.4    Maisonpierre, P.C.5    Davis, S.6
  • 122
    • 0034786155 scopus 로고    scopus 로고
    • Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial
    • Reitamo S., Spuls P., Sassolas B., Lahfa M., Claudy A., and Griffiths C.E. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145 (2001) 438-445
    • (2001) Br J Dermatol , vol.145 , pp. 438-445
    • Reitamo, S.1    Spuls, P.2    Sassolas, B.3    Lahfa, M.4    Claudy, A.5    Griffiths, C.E.6
  • 123
    • 17644374126 scopus 로고    scopus 로고
    • Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial
    • Ormerod A.D., Shah S.A., Copeland P., Omar G., and Winfield A. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 152 (2005) 758-764
    • (2005) Br J Dermatol , vol.152 , pp. 758-764
    • Ormerod, A.D.1    Shah, S.A.2    Copeland, P.3    Omar, G.4    Winfield, A.5
  • 124
    • 33745305095 scopus 로고    scopus 로고
    • Anti-angiogenic drugs: from bench to clinical trials
    • Quesada A.R., Munoz-Chapuli R., and Medina M.A. Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26 (2006) 483-530
    • (2006) Med Res Rev , vol.26 , pp. 483-530
    • Quesada, A.R.1    Munoz-Chapuli, R.2    Medina, M.A.3
  • 125
    • 33847020465 scopus 로고    scopus 로고
    • SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis
    • Keshtgarpour M., and Dudek A.Z. SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis. Transl Res 149 (2007) 103-106
    • (2007) Transl Res , vol.149 , pp. 103-106
    • Keshtgarpour, M.1    Dudek, A.Z.2
  • 126
    • 25444468047 scopus 로고    scopus 로고
    • Dobesilate in the treatment of plaque psoriasis
    • Cuevas P., and Arrazola J.M. Dobesilate in the treatment of plaque psoriasis. Eur J Med Res 10 (2005) 373-376
    • (2005) Eur J Med Res , vol.10 , pp. 373-376
    • Cuevas, P.1    Arrazola, J.M.2
  • 128
    • 34648830374 scopus 로고    scopus 로고
    • Lymphangiogenesis and angiogenesis in non-phymatous rosacea
    • Gomaa A.H., Yaar M., Eyada M.M., and Bhawan J. Lymphangiogenesis and angiogenesis in non-phymatous rosacea. J Cutan Pathol 34 (2007) 748-753
    • (2007) J Cutan Pathol , vol.34 , pp. 748-753
    • Gomaa, A.H.1    Yaar, M.2    Eyada, M.M.3    Bhawan, J.4
  • 130
    • 48349087831 scopus 로고    scopus 로고
    • Antimicrobial peptides and the skin immune defense system
    • Schauber J., and Gallo R.L. Antimicrobial peptides and the skin immune defense system. J Allergy Clin Immunol 122 (2008) 261-266
    • (2008) J Allergy Clin Immunol , vol.122 , pp. 261-266
    • Schauber, J.1    Gallo, R.L.2
  • 131
    • 0345074069 scopus 로고    scopus 로고
    • Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide
    • Di Nardo A., Vitiello A., and Gallo R.L. Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide. J Immunol 170 (2003) 2274-2278
    • (2003) J Immunol , vol.170 , pp. 2274-2278
    • Di Nardo, A.1    Vitiello, A.2    Gallo, R.L.3
  • 132
    • 22144457975 scopus 로고    scopus 로고
    • Cutaneous defense mechanisms by antimicrobial peptides
    • Braff M.H., Bardan A., Nizet V., and Gallo R.L. Cutaneous defense mechanisms by antimicrobial peptides. J Invest Dermatol 125 (2005) 9-13
    • (2005) J Invest Dermatol , vol.125 , pp. 9-13
    • Braff, M.H.1    Bardan, A.2    Nizet, V.3    Gallo, R.L.4
  • 134
    • 84920106848 scopus 로고    scopus 로고
    • Deindl E., and Kupatt C. (Eds), Springer-Verlag, New York
    • In: Deindl E., and Kupatt C. (Eds). Therapeutic neovascularization: quo vadis? (2007), Springer-Verlag, New York
    • (2007) Therapeutic neovascularization: quo vadis?
  • 135
    • 42449090687 scopus 로고    scopus 로고
    • LL-37 regulates the overexpression of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes
    • Rodriguez-Martinez S., Cancino-Diaz J.C., Vargas-Zuniga L.M., and Cancino-Diaz M.E. LL-37 regulates the overexpression of vascular endothelial growth factor (VEGF) and c-IAP-2 in human keratinocytes. Int J Dermatol 47 (2008) 457-462
    • (2008) Int J Dermatol , vol.47 , pp. 457-462
    • Rodriguez-Martinez, S.1    Cancino-Diaz, J.C.2    Vargas-Zuniga, L.M.3    Cancino-Diaz, M.E.4
  • 136
    • 34547660319 scopus 로고    scopus 로고
    • Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea
    • Yamasaki K., Di Nardo A., Bardan A., Murakami M., Ohtake T., Coda A., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 13 (2007) 975-980
    • (2007) Nat Med , vol.13 , pp. 975-980
    • Yamasaki, K.1    Di Nardo, A.2    Bardan, A.3    Murakami, M.4    Ohtake, T.5    Coda, A.6
  • 137
    • 27744572068 scopus 로고    scopus 로고
    • Therapeutic response of rosacea to dobesilate
    • Cuevas P., and Arrazola J.M. Therapeutic response of rosacea to dobesilate. Eur J Med Res 10 (2005) 454-456
    • (2005) Eur J Med Res , vol.10 , pp. 454-456
    • Cuevas, P.1    Arrazola, J.M.2
  • 138
    • 0034783801 scopus 로고    scopus 로고
    • Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis
    • Chan L.S., Robinson N., and Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. J Invest Dermatol 117 (2001) 977-983
    • (2001) J Invest Dermatol , vol.117 , pp. 977-983
    • Chan, L.S.1    Robinson, N.2    Xu, L.3
  • 139
    • 25444517290 scopus 로고    scopus 로고
    • The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE
    • Chen L., Lin S.X., Overbergh L., Mathieu C., and Chan L.S. The disease progression in the keratin 14 IL-4-transgenic mouse model of atopic dermatitis parallels the up-regulation of B cell activation molecules, proliferation and surface and serum IgE. Clin Exp Immunol 142 (2005) 21-30
    • (2005) Clin Exp Immunol , vol.142 , pp. 21-30
    • Chen, L.1    Lin, S.X.2    Overbergh, L.3    Mathieu, C.4    Chan, L.S.5
  • 140
    • 9644302965 scopus 로고    scopus 로고
    • Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model
    • Chen L., Martinez O., Overbergh L., Mathieu C., Prabhakar B.S., and Chan L.S. Early up-regulation of Th2 cytokines and late surge of Th1 cytokines in an atopic dermatitis model. Clin Exp Immunol 138 (2004) 375-387
    • (2004) Clin Exp Immunol , vol.138 , pp. 375-387
    • Chen, L.1    Martinez, O.2    Overbergh, L.3    Mathieu, C.4    Prabhakar, B.S.5    Chan, L.S.6
  • 141
    • 13544256255 scopus 로고    scopus 로고
    • Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis
    • Chen L., Martinez O., Venkataramani P., Lin S.X., Prabhakar B.S., and Chan L.S. Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. Clin Exp Immunol 139 (2005) 189-201
    • (2005) Clin Exp Immunol , vol.139 , pp. 189-201
    • Chen, L.1    Martinez, O.2    Venkataramani, P.3    Lin, S.X.4    Prabhakar, B.S.5    Chan, L.S.6
  • 142
    • 25144450231 scopus 로고    scopus 로고
    • Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis
    • Agha-Majzoub R., Becker R.P., Schraufnagel D.E., and Chan L.S. Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation 12 (2005) 455-476
    • (2005) Microcirculation , vol.12 , pp. 455-476
    • Agha-Majzoub, R.1    Becker, R.P.2    Schraufnagel, D.E.3    Chan, L.S.4
  • 143
    • 38049161744 scopus 로고    scopus 로고
    • The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis
    • Chen L., Marble D.J., Agha R., Peterson J.D., Becker R.P., Jin T., et al. The progression of inflammation parallels the dermal angiogenesis in a keratin 14 IL-4-transgenic model of atopic dermatitis. Microcirculation 15 (2008) 49-64
    • (2008) Microcirculation , vol.15 , pp. 49-64
    • Chen, L.1    Marble, D.J.2    Agha, R.3    Peterson, J.D.4    Becker, R.P.5    Jin, T.6
  • 144
    • 33344476172 scopus 로고    scopus 로고
    • Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis
    • Zhang Y., Matsuo H., and Morita E. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch Dermatol Res 297 (2006) 425-429
    • (2006) Arch Dermatol Res , vol.297 , pp. 425-429
    • Zhang, Y.1    Matsuo, H.2    Morita, E.3
  • 145
    • 12444299991 scopus 로고    scopus 로고
    • Mast cells and vasculature in atopic dermatitis-potential stimulus of neoangiogenesis
    • Groneberg D.A., Bester C., Grutzkau A., Serowka F., Fischer A., Henz B.M., et al. Mast cells and vasculature in atopic dermatitis-potential stimulus of neoangiogenesis. Allergy 60 (2005) 90-97
    • (2005) Allergy , vol.60 , pp. 90-97
    • Groneberg, D.A.1    Bester, C.2    Grutzkau, A.3    Serowka, F.4    Fischer, A.5    Henz, B.M.6
  • 146
    • 0018581426 scopus 로고
    • Mast cell population density, blood vessel density and histamine content in normal human skin
    • Eady R.A., Cowen T., Marshall T.F., Plummer V., and Greaves M.W. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol 100 (1979) 623-633
    • (1979) Br J Dermatol , vol.100 , pp. 623-633
    • Eady, R.A.1    Cowen, T.2    Marshall, T.F.3    Plummer, V.4    Greaves, M.W.5
  • 147
    • 2142657200 scopus 로고    scopus 로고
    • Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts
    • Wu Y., Zhang Q., Ann D.K., Akhondzadeh A., Duong H.S., Messadi D.V., et al. Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts. Am J Physiol Cell Physiol 286 (2004) C905-C912
    • (2004) Am J Physiol Cell Physiol , vol.286
    • Wu, Y.1    Zhang, Q.2    Ann, D.K.3    Akhondzadeh, A.4    Duong, H.S.5    Messadi, D.V.6
  • 148
    • 33846258102 scopus 로고    scopus 로고
    • Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion
    • Ong C.T., Khoo Y.T., Tan E.K., Mukhopadhyay A., Do D.V., Han H.C., et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 211 (2007) 95-108
    • (2007) J Pathol , vol.211 , pp. 95-108
    • Ong, C.T.1    Khoo, Y.T.2    Tan, E.K.3    Mukhopadhyay, A.4    Do, D.V.5    Han, H.C.6
  • 149
    • 59949086075 scopus 로고    scopus 로고
    • Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice
    • Goren I., Müller E., Schiefelbein D., Gutwein P., Seitz O., Pfeilschifter J., et al. Akt1 controls insulin-driven VEGF biosynthesis from keratinocytes: implications for normal and diabetes-impaired skin repair in mice. J Invest Dermatol 129 (2009) 752-764
    • (2009) J Invest Dermatol , vol.129 , pp. 752-764
    • Goren, I.1    Müller, E.2    Schiefelbein, D.3    Gutwein, P.4    Seitz, O.5    Pfeilschifter, J.6
  • 150
    • 66849094045 scopus 로고    scopus 로고
    • Recombinant human platelet-derived growth factor enhances repair of cutaneous full-thickness excision by increasing the phosphorylation of extracellular signal-regulated kinase in diabetic rat
    • Cheng B., Liu H., Fu X., Sheng Z., and Sun T. Recombinant human platelet-derived growth factor enhances repair of cutaneous full-thickness excision by increasing the phosphorylation of extracellular signal-regulated kinase in diabetic rat. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 20 (2006) 1093-1098
    • (2006) Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi , vol.20 , pp. 1093-1098
    • Cheng, B.1    Liu, H.2    Fu, X.3    Sheng, Z.4    Sun, T.5
  • 151
    • 33745513688 scopus 로고    scopus 로고
    • Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers
    • Steed D.L. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity ulcers. Plast Reconstr Surg 117 7 suppl (2006) 143S-149S
    • (2006) Plast Reconstr Surg , vol.117 , Issue.7 SUPPL
    • Steed, D.L.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.